CTLA4 and prostate neoplasm: To evaluate the generalizability of our observations, we tested the therapeutic efficacy of the triple combination of PIC + RT + anti-CTLA-4 in the MyC-CaP prostate tumor model in syngeneic male FVB/NTac mice and the orthotopic TC11 breast tumor model in syngeneic female FVB/NTac mice (Fig. 6a).